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Conflict of Interest and the JID
This editor could not escape his work by reading the Sunday New York Times (23 July, 2006); the second editorial, “Our 
Conflicted Medical Journals,” discussed recent 
articles in the Journal of the American Medical 
Association and Neuropsychopharmacology in 
which authors failed to declare potential con-
flicts of interest (COI). Disclosure of such conflicts 
is important, as knowing an author’s potential 
biases helps readers assess the information and 
opinions presented in an article, while failure to 
disclose COI may be interpreted as an effort to 
deliberately mislead the reader. The COI policy 
of the Journal of Investigative Dermatology (JID) is 
reviewed below. How that policy has been imple-
mented was analyzed by examination of the June, 
July, and August 2006 issues of the Journal.
The JID follows the International Committee 
of Medical Journal Editors’ recommendations 
of February 2006 on declaring conflict of inter-
est in medical publications, as detailed in our 
Editorial Policies (http://www.nature.com/jid/
editorial_policies.html). The author’s declara-
tion is published in a separately marked section 
near the end of each article, labeled “Conflict of 
Interest”; this appears in the online and the print-
ed text of all articles, including Commentaries, 
Perspectives, Original Articles, and Letters to 
the Editor. During online submission, authors 
are prompted to provide a statement of COI; a 
COI form, completed by each individual author, 
is required by the Journal before any accepted 
manuscript will be sent for publication.
The most commonly published statement, 
given in 95 of the 101 articles published dur-
ing the three-month period reviewed, is that 
“the author(s) state(s) no conflict of interest.” 
However, authors disclosed many types of 
relationships in these three issues. These are 
summarized in Table 1.
Is the JID capturing all of the potential conflicts 
of interest of its authors? Probably not. There may 
be inadvertent omissions, intentional omissions 
or omissions because authors thought a conflict 
was trivial or not relevant. When “Dr. Z” (also 
known as CEO Dieter Zetsche) appears in the 
United States DaimlerChrysler television com-
mercial, discussing safety with the goal of sell-
ing more cars, does he have conflict of interest? 
Must that conflict of interest be declared in the 
ad — or is this covered in the first seconds of the 
spot, where his name and title are revealed? Must 
authors employed by a company declare such 
in a COI statement, or is that implicit? Even so, 
should it be stated? All the authors of one JID arti-
cle from the August issue (Stamatas et al., 2006) 
were employed by a pharmaceutical company; 
this was clear in the author affiliations on the first 
page of the article, but no COI was declared. We 
are reviewing our policy on this issue.
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Table 1. Confl icts of interest declared by authors in June, July, and August issues of JID
Reference Issue Article type Confl ict of interest declared
Grichnik, 2006 June Commentary Author was a major shareholder in and founder of a company with 
a product potentially relevant to the article commented upon
Jimenez et al., 2006 June Original Article Individual authors were employees of, the owner of, and a consul-
tant for the company funding the research
Querfeld et al., 2006 July Original Article One author was a consultant for the company donating the drug 
used for the in vitro studies reported
Jung et al., 2006 August Original Article One author had a commercial interest in the company, which 
employs that and one other author
Sandilands et al., 2006 August Original Article Two of the authors had fi led patents for genetic tests related to the 
report
Barnetson et al., 2006 August Original Article One author was on the medical advisory panel for a company, and 
other authors were employees of that company
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The JID in particular, as well as most other journals, does not 
want to become the COI investigative squad. We count on our 
authors to be forthright with us. Do authors have concerns that 
declared interests will decrease their chance of publication, or 
slow the process of acceptance? Probably. However, the editor-
ial board realizes that the world is complex and that excellent 
data can be generated from sources with close connections to 
industry. We are used to parsing and studying scientific pro-
cesses with the utmost of subtlety. Ethics is often thought of as 
a dichotomous variable: good or bad; its practical application 
and analysis of the issues related to publication and disclosure 
must be treated as more complex than is usually done in the lay 
press. Material gain of the investigators from science is nothing 
new; patent applications have been intrinsic to science for hun-
dreds of years. We will be vigilant, thoughtful, and measured. 
All authors committed to the highest standards of scientific 
conduct — which includes revealing sources of potential bias 
— are welcome to submit their work to the JID.
Lowell A. Goldsmith
Editor
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